| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0969-2126(01)00192-7 |
| P698 | PubMed publication ID | 8590019 |
| P2093 | author name string | B Liu | |
| H Mitsuya | |||
| E T Baldwin | |||
| T N Bhat | |||
| Y Kiso | |||
| J W Erickson | |||
| I A Topol | |||
| T Mimoto | |||
| S Gulnik | |||
| P2860 | cites work | Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling | Q27642043 |
| Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere | Q27656274 | ||
| X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor | Q27678325 | ||
| Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor | Q27729870 | ||
| Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase | Q27730261 | ||
| Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors | Q27731528 | ||
| Bound water molecules and conformational stabilization help mediate an antigen-antibody association | Q27731557 | ||
| On the size of the active site in proteases. I. Papain | Q27860826 | ||
| Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine | Q28317154 | ||
| KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic | Q28325655 | ||
| Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic | Q28325724 | ||
| Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes | Q28334989 | ||
| Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor | Q28369516 | ||
| Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease | Q28378274 | ||
| Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor | Q28378387 | ||
| In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine | Q28378709 | ||
| The HIV-1 protease as a therapeutic target for AIDS | Q35898324 | ||
| HIV protease: a novel chemotherapeutic target for AIDS. | Q37254750 | ||
| Structure-based inhibitors of HIV-1 protease | Q40835286 | ||
| Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere | Q42289255 | ||
| High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies | Q42631588 | ||
| Determinants of repressor/operator recognition from the structure of the trp operator binding site. | Q54637305 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 581-90 | |
| P577 | publication date | 1995-06-15 | |
| P1433 | published in | Structure | Q15709970 |
| P1476 | title | Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine | |
| P478 | volume | 3 |
| Q35742512 | A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies |
| Q42557837 | A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking |
| Q28344457 | A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site |
| Q46543722 | Accelerated Poisson-Boltzmann calculations for static and dynamic systems |
| Q39343604 | Accounting for ligand conformational restriction in calculations of protein-ligand binding affinities |
| Q35660425 | Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. |
| Q51304233 | AutoDock-GIST: Incorporating Thermodynamics of Active-Site Water into Scoring Function for Accurate Protein-Ligand Docking. |
| Q26779035 | Charting a Path to Success in Virtual Screening |
| Q51775733 | Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors. |
| Q42001082 | Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272. |
| Q30770159 | DREAM++: flexible docking program for virtual combinatorial libraries |
| Q41094530 | Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere |
| Q44103766 | Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. |
| Q44190842 | Enhanced docking with the mining minima optimizer: acceleration and side-chain flexibility |
| Q73047075 | Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function |
| Q33906239 | Genotypic testing for human immunodeficiency virus type 1 drug resistance |
| Q33834118 | HIV protease: enzyme function and drug resistance |
| Q44371788 | HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization |
| Q40317435 | Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations |
| Q37279262 | Ions and inhibitors in the binding site of HIV protease: comparison of Monte Carlo simulations and the linearized Poisson-Boltzmann theory |
| Q35560481 | JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. |
| Q52066525 | Ligand-receptor docking with the Mining Minima optimizer. |
| Q36658560 | Linkers in the structural biology of protein-protein interactions |
| Q34545639 | Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate |
| Q35987132 | Modeling Protein-Ligand Binding by Mining Minima |
| Q38011251 | Modeling molecular recognition: theory and application |
| Q33511631 | Molecular docking screens using comparative models of proteins |
| Q41882569 | Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease |
| Q35612259 | Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding |
| Q28378834 | NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces species |
| Q51377144 | Placevent: an algorithm for prediction of explicit solvent atom distribution-application to HIV-1 protease and F-ATP synthase. |
| Q34010283 | Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis |
| Q47655078 | Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors |
| Q77435885 | Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility |
| Q38034245 | Revisiting ligand-induced conformational changes in proteins: essence, advancements, implications and future challenges. |
| Q27654045 | Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography |
| Q28376032 | Structure-based design of diaminopyranosides as a novel inhibitor core unit of HIV proteases |
| Q27638967 | Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes |
| Q43542759 | Synthesis and biological evaluation of prodrug-type anti-HIV agents: ester conjugates of carboxylic acid-containing dipeptide HIV protease inhibitors and a reverse transcriptase inhibitor. |
| Q31717913 | Synthesis of di- and tripeptide analogues containing alpha-ketoamide as a new core structure for inhibition of HIV-1 protease |
| Q64987688 | The impact of interior dielectric constant and entropic change on HIV-1 complex binding free energy prediction. |
| Q72033327 | The not-so-great escape |
| Q28344884 | Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor |
| Q30480872 | Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease |
| Q36715297 | Water at biomolecular binding interfaces |
Search more.